Companies /Healthcare

Regeneron Pharmaceuticals Inc

NASDAQ: REGN Biotechnology
$790.74
▼ $5.60 (−0.70%) today
Markets closed · 11:36pm ET

REGN Coverage Page 12

11:53am ET
Health and Healthcare

Have Analysts Fully Priced in Praluent to Regeneron?

ThinkstockRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (NYSE: SNY) announced last Friday that the U.S. Food and Drug Administration (FDA) approved Praluent (alirocumab) Injection. Praluent is indicated as an adjunct to diet…

Chris Lange